1.Response to therapy of 13 children with rhabdomyosarcoma.
Ying XU ; Suo-Qin TANG ; Jian-Wen WANG ; Ying LIU ; Li-Zhen LIU
Chinese Journal of Contemporary Pediatrics 2008;10(2):163-166
OBJECTIVETo study the clinical response to comprehensive therapy in children with rhabdomyosarcoma.
METHODSClinical data of 13 children (8 males and 5 females) with rhabdomyosarcoma from January 1998 through October 2005 were retrospectively studied. Their ages ranged from 7 months to 12 years. The 13 cases of rhabdomyosarcoma consisted of 2 cases in stage I, 2 cases in stage II, 3 cases in stage III, and 6 cases in stage IV. Rhabdomyosarcoma was confirmed by biopsy, 12 cases (92.3%) presenting as embryonal type and 1 as alveolar type in histology. One patient underwent surgery treatment alone, one patient received surgery plus local radiation treatment, one patient received surgery plus chemotherapy and 10 patients were administered with a combination of surgery, local radiation treatment and chemotherapy. The chemotherapy protocol before 2002 was VDCA, VAC or VadrC. After 2002, the COG protocol was employed, with CDV+IE for stage III, and CT+VAC or CT+VAC+VCT for stage IV patients.
RESULTSThe 2-year overall survival was 60% in the 10 patients who received a combination of surgery, local radiation treatment and chemotherapy, but the three patients died without receiving combination therapy. The 2-year overall survival in the 13 patients was 46.2%. The 2-year overall survival of the patients after 2002 (60%, 3/5) was higher than that before 2002 (37.5%, 3/8).
CONCLUSIONSEmbryonal rhabdomyosarcoma dominates the histology type in children, which is highly malignant. A combination therapy of surgery, local radiation and chemotherapy can result in a satisfactory therapeutic effect in children with rhabdomyosarcoma.
Child ; Child, Preschool ; Combined Modality Therapy ; Female ; Humans ; Infant ; Male ; Retrospective Studies ; Rhabdomyosarcoma ; mortality ; therapy
2.Childhood rhabdomyosarcoma: a retrospective review of 23 cases.
Min ZHAO ; Chen FENG ; Jian-Wen WANG ; Ying LIU ; Suo-Qin TANG
Chinese Journal of Contemporary Pediatrics 2011;13(8):657-660
OBJECTIVETo study the clinical characteristics, treatment and outcome of childhood rhabdomyosarcoma.
METHODSThe clinical data of 23 children with rhabdomyosarcoma from January, 1998 to October, 2008 were retrospectively reviewed.
RESULTSOf the 23 cases, 15 were male and 8 were female, with a mean age of 5 years old (7 months to 12 years old). Based on the American IRS staging system, 2 cases were in stage I, 4 cases in stage II, 8 cases in stage III, and 9 were in stage IV. The primary sites were found in head and neck (14 cases), extremities (4 cases), bladder (2 cases), kidney (1 case), post-peritoneum (1 case) and bile duct (1 case). All of the children were confirmed with rhabdomyosarcoma by biopsy and immunohistochemistry. The clinical manifestations were related to the tumor tissues-induced space occupying, compression and erosion and were aspecific. The patients in different IRS stages were given different treatment regimens. The chemotherapy regimens VDCA, VAC or VadrC were used before 2002. After 2002, the Children's Oncology Group (COG) protocol was employed. The two-year survival rate was 63% in 19 patients who received a combination of surgery, chemotherapy and radiotherapy, but none of 4 patients who received a surgery alone or a combination of surgery and chemotherapy or radiotherapy survived more than two years.
CONCLUSIONSThe clinical manifestations of childhood rhabdomyosarcoma are not specific. A combination therapy including surgery, chemotherapy and radiation is effective to the improvement of the survival rate in children with rhabdomyosarcoma.
Child ; Child, Preschool ; Combined Modality Therapy ; Female ; Humans ; Infant ; Male ; Retrospective Studies ; Rhabdomyosarcoma ; mortality ; therapy
3.Clinical features and outcomes of neuroblastoma patients aged above 5 years.
Yi ZHANG ; Wei-Ling ZHANG ; Dong-Sheng HUANG ; Tao HAN ; Tian ZHI ; Jing LI ; You YI ; Yuan WEN ; Fan LI ; Yan-Yan MEI ; Yan-Yan DU
Chinese Journal of Contemporary Pediatrics 2016;18(12):1217-1221
OBJECTIVETo investigate the clinical features and outcomes of neuroblastoma (NB) children aged above 5 years, and to provide a theoretical basis for improving prognosis.
METHODSA retrospective analysis was performed for the clinical data of 54 previously untreated NB children, and their clinical features and outcome were analyzed. The Kaplan-Meier method was used for survival analysis.
RESULTSAmong the 54 children, there were 36 boys and 18 girls, and all of them had stage 3 or 4 NB. Of all the children, 41 (41/54, 76%) had retroperitoneal space-occupying lesions, 10 (10/54, 18%) had mediastinal space-occupying lesions, 2 (2/54, 4%) had intraspinal space-occupying lesions, and 1 (1/54, 2%) had pelvic space-occupying lesions. At the end of the follow-up, 30 children (30/54, 56%) survived, among whom 23 (77%) achieved disease-free survival (9 achieved complete remission after chemotherapy for recurrence), 6 (20%) achieved partial remission of tumor (all of them received chemotherapy again due to recurrence), and 1 (3%) experienced progression (with progression after chemotherapy again due to recurrence); 24 children (44%) died, among whom 22 died after chemotherapy again due to recurrence and 2 died of multiple organ failure during the first treatment. According to the Kaplan-Meier survival analysis, the mean survival time was 53.8 months, and the children with stage 3 NB had a significantly higher overall survival rate than those with stage 4 NB (80% vs 53%; p<0.01). The children with recurrence had a significantly lower mean survival time than those without recurrence (51.68 months vs 62.57 months; p<0.01).
CONCLUSIONSOlder children often have late-stage NB, but standard treatment can improve their outcomes.
Adolescent ; Child ; Child, Preschool ; Combined Modality Therapy ; Female ; Humans ; Male ; Neuroblastoma ; mortality ; therapy ; Retrospective Studies
4.Treatment of unresectable esophageal carcinoma by stenting with or without radiochemotherapy.
Jian-hua FU ; Tie-hua RONG ; Xiao-dong LI ; Hui YU ; Guo-wei MA ; Hua-qing MIN
Chinese Journal of Oncology 2004;26(2):109-111
OBJECTIVETo evaluate the benefits of post-stenting radiotherapy and/or chemotherapy for unresectable esophageal carcinoma.
METHODSFifty-three patients with unresectable esophageal carcinoma were randomly divided into two groups: patients in group A (n = 27) were treated with stenting alone, and those in group B (n = 26) were treated with stenting followed by radiotherapy and/or chemotherapy. Comparison was made by assessing their survival time, quality of life (QOL), degree of dysphagia, and stenting-related morbidity, respectively.
RESULTSThere was no statistically significant improvement in dysphagia and QOL between the two groups. Although there was no difference in the frequency of stenting-related complications, re-stenosis occurred much less frequently in group B patients (P = 0.007). The mean survival time of patients was 245 +/- 41 days and 262 +/- 43 days in group A and group B, respectively. There was no significant difference between the two groups (P = 0.813).
CONCLUSIONBesides decreased recurrence of stenosis, post-stenting radiotherapy and/or chemotherapy does not provide additional benefits for survival.
Combined Modality Therapy ; Esophageal Neoplasms ; mortality ; therapy ; Female ; Humans ; Male ; Stents
5.An inoperable osteosarcoma of the maxillary sinus with long-term survival after chemotherapy and radiotherapy.
Yong Jin KIM ; Jin Young KIM ; Hee Jin SEONG ; Woo Young PARK ; Sun Young KWON ; Young Rok DO ; Hong Suk SONG
Korean Journal of Medicine 2007;72(4):437-440
Maxillary osteosarcoma is an aggressive disease with a high mortality rate. Extensive surgical resection is accepted as the standard treatment for the disease. The beneficial role of chemotherapy and radiotherapy in the treatment of the disorders is uncertain. We experienced a case of an osteosarcoma of the maxillary sinus. Paranasal sinus computed tomography showed a huge solid mass lesion at the left maxillary sinus walls. An endoscopic biopsy showed an osteoblastic type osteosarcoma. In this case, radical surgery was impossible, and the patient was treated with chemotherapy and radiotherapy. This regimen involved four cycles of chemotherapy, cisplatin, 100 mg/m2 intravenously on the first day of weeks 1, 4, 7, and 10, and doxorubicin, 25 mg/m2 per day on the first 3 days of weeks 1, 4. 7. and 10, followed by external beam radiotherapy with a total dose of 6,600 cGy. We report here a case of an inoperable osteosarcoma of the maxilla with long-term survival after chemotherapy and radiotherapy with an accompanying review of the literature.
Biopsy
;
Cisplatin
;
Combined Modality Therapy
;
Doxorubicin
;
Drug Therapy*
;
Humans
;
Maxilla
;
Maxillary Sinus*
;
Mortality
;
Osteoblasts
;
Osteosarcoma*
;
Radiotherapy*
6.Clinical features and prognosis of advanced neuroblastoma in children.
Xiao-Ning GAO ; Suo-Qin TANG ; Ji LIN
Chinese Journal of Contemporary Pediatrics 2007;9(4):351-354
OBJECTIVETo investigate the clinical features, treatment modalities and the prognosis of advanced neuroblastoma in children.
METHODSThe medical records of 63 children with stage III or IV neuroblastoma from January 1996 to December 2005 were retrospectively reviewed. Sixty patients were treated by tumor resection and (or) chemotherapy and (or) radiation. Fourteen out of the 60 patients received another autologous peripheral blood stem cell transplantation.
RESULTSOf the 63 patients with advanced neuroblastoma, the male/female ratio was 2.7:1 and the median age at diagnosis was 4 years old. Most of the initial symptoms included pyrexia, abdominal pain, abdominal mass, and leg or articular pain. Primary tumor sites were adrenal (38%), retroperitoneal (35%), mediastinal (17%), pelvic (6%) and cervical (2%). The sites of metastasis at diagnosis included local (41%) and (or) distant (37%) lymph nodes, bone marrow (60%), bone (46%) and liver (16%). The median survival time of the 63 patients was 32.7 months. The 2-year survival rate was 44.3%. Statistical analysis demonstrated that unfavorable survival prognostic factors were the following: age > 1 year at diagnosis (P < 0.05); serum neuro-specific enolase > 100 mg/L (P < 0.05); serum lactic dehydrogenase > 1500 U/L (P < 0.01); serum ferritin >150 mg/L (P < 0.05). The overall survival period of the patients was prolonged through total resection of the primary tumor (P < 0.05). Intensive chemotherapy in combination with autologous peripheral blood stem cell transplantation could also result in a prolonged overall survival period (P < 0.01).
CONCLUSIONSNeuroblastoma with advanced stages often presents with various clinical manifestations and has a poor prognosis. It is beneficial to improve the prognosis of neuroblastoma through an early diagnosis and a comprehensive therapy including total resection of the primary tumor, autologous peripheral blood stem cell transplantation and intensive chemotherapy.
Adolescent ; Child ; Child, Preschool ; Combined Modality Therapy ; Female ; Humans ; Infant ; Male ; Neuroblastoma ; mortality ; therapy ; Prognosis
7.Diagnosis and treatment of prostatic malignant mesenchymal tumors: Analysis of 20 cases.
Ke-bing YANG ; Xiang-yi ZHENG ; Jin-dan LUO ; Shan-wen CHEN ; Hong-Zhou MENG ; Bai-hua SHEN ; Song-liang CAI ; Li-ping XIE
National Journal of Andrology 2015;21(4):308-314
OBJECTIVETo explore the diagnosis, treatment, and prognosis of prostatic malignant mesenchymal tumors (PMMT).
METHODSWe retrospectively analyzed the clinical and follow-up data about 20 cases of PMMT and reviewed the literature relevant to the diagnosis, treatment, and prognosis of the disease.
RESULTSBased on the results of pathology and immunohistochemistry, the 20 PMMT cases included leiomyosarcoma (n = 7), rhabdomyosarcoma (n = 5), prostatic stromal sarcoma (n = 3), chondrosarcoma (n = 1), and undifferentiated PMMT (n = 4). Twelve of the patients were treated by radical prostatectomy (3 concurrently by sigmoid colostomy and 1 by cystostomy), 2 by pelvic tumor resection following arterial embolization, 1 by total pelvic exenteration, 1 by colostomy with pelvic lymph node biopsy, and 4 by conservative therapy because of metastasis to the lung, pelvis and bone. Of the 20 patients, 9 died of systemic metastasis within 3 months after treatment, 3 died at 6, 7, and 14 months, respectively, 3 survived with tumor for 5, 11, and 12 months, respectively, 2 survived without tumor for 12 and 24 months so far, all subjected to periodic chemotherapy postoperatively, and 3 lost to follow-up.
CONCLUSIONPMMT is a tumor of high malignancy and rapid progression, for which transrectal ultrasound-guided biopsy remains the main diagnostic method. The clinical stage of the tumor is an important factor influencing its prognosis and the survival rate of the patients can be improved by early diagnosis and combined therapy dominated by radical prostatectomy.
Combined Modality Therapy ; methods ; Humans ; Immunohistochemistry ; Male ; Mesenchymoma ; mortality ; pathology ; therapy ; Prognosis ; Prostatectomy ; Prostatic Neoplasms ; mortality ; pathology ; therapy ; Retrospective Studies
8.Effect of resection margin and tumor number on survival of patients with small liver cancer.
Weiqi RONG ; Weibo YU ; Fan WU ; Jianxiong WU ; Email: DR.WUJX@HOTMAIL.COM. ; Liming WANG ; Fei TIAN ; Songlin AN ; Li FENG ; Faqiang LIU
Chinese Journal of Oncology 2015;37(12):928-931
OBJECTIVETo explore the significance of resection margin and tumor number on survival of patients with small liver cancer after hepatectomy.
METHODSWe collected 219 cases with small liver cancer undergoing hepatectomy in Cancer Hospital, Chinese Academy of Medical Sciences between December 2003 to July 2013. The survival rates were compared by log-rank test between two resection margin groups (≥ 1 cm vs. <1 cm), different tumor number groups (single tumor vs. multiple tumors). We also performed a multifactor analysis by Cox model.
RESULTSThe 1-, 3-, 5- and 10- year overall survival rates were 95.9%, 85.3%, 67.8% and 53.3%, respectively, in all patients. The median survival time was 28 months in the group of <1 cm resection margin and 36 months in the group of ≥ 1 cm resection margin (P=0.249). The median survival time was 36 months in the group of single tumor and 26 months in the group of multiple tumors (P=0.448). The multifactor analysis also did not show significant effect of resection margin and tumor number on the patients' survival.
CONCLUSIONSFor small liver cancer, the resection margin of 1 cm might be advised. Increasing resection margin in further could probably not improve therapeutic effect. Standardized operation and combined treatment will decrease the negative influence of multiple tumors on overall survival.
Combined Modality Therapy ; Hepatectomy ; Humans ; Liver Neoplasms ; mortality ; pathology ; surgery ; Survival Rate ; Time Factors
9.Results of combined therapy for 1260 patients with small cell lung cancer.
Dongfu CHEN ; Xiangru ZHANG ; Weibo YIN ; Yan SUN ; Yanjun MIAO ; Fengyi FENG ; Jinwan WANG ; Mei WANG ; Hongxing ZHANG ; Qinfu FENG ; Binghe XU ; Yuankai SHI
Chinese Journal of Oncology 2002;24(6):602-604
OBJECTIVETo evaluate the efficacy of combined modality treatment and determine the prognostic factors for small cell lung cancer (SCLC).
METHODSFrom January 1974 to December 1995, 1260 patients with SCLC treated were retrospectively evaluated, with limited lesions in 732 patients, extensive lesions in 500 and stage unrecorded in 28. 553 patients were alloted into chemotherapy + radiotherapy (C + R) group, 355 into C + R + C group, 97 into R + C group, 126 into C group, 64 into R group and 65 into surgery (S + C + R) group. Patients with limited lesions received 2 - 4 cycles of chemotherapy including COMC, COMP, COMVP and CE-CAP. Radiotherapy was given to a dose of 40 - 70 Gy/4 - 7 w. Radiation portals for patients with limited lesions encompassed the primary tumor, hilar lymphatic drainage areas, partial mediastinum and bilateral supraclavicular regions. Patients with extensive lesions mainly received chemotherapy with or without palliative irradiation.
RESULTSThe overall CR and PR rates were 26.7% and 52.3%. Local recurrence and distant metastasis rates were 58.8% and 61.5%. The 1-, 3- and 5-year survival rates were 50.2%, 14.7% and 11.7%, with median survival time of 12 months. The era, sex, age, tumor stage and treatment modality were all significant prognostic factors by both uni-variate and multi-variate analyses (P < 0.05). The result of S + C + R rated the best among these modalities and the result of C + R + C was superior to C + R, though the difference of which was not significant.
CONCLUSIONSurgical resection should be considered as one part of comprehensive therapy for small cell lung cancer patients with limited lesions whenever possible. On top of routine chemotherapy early administration of radiotherapy is advisable.
Adult ; Antineoplastic Combined Chemotherapy Protocols ; Carcinoma, Small Cell ; mortality ; therapy ; Combined Modality Therapy ; Female ; Humans ; Lung Neoplasms ; mortality ; therapy ; Male ; Middle Aged ; Radiotherapy ; Survival Rate ; Treatment Outcome
10.Intraoperative radiotherapy for 30 esophageal carcinoma patients.
Fu-lai YAN ; Xing-ming ZHOU ; Qi-xun CHEN ; Rong-xuan JIANG ; Jun FANG ; Yan-hong LIAN ; Xiao ZHENG ; Xiu-yong CHEN ; Yuan ZHU ; Xiao-yun DI ; Jian WANG
Chinese Journal of Oncology 2003;25(2):178-180
OBJECTIVETo analyze the complications and treatment results of intraoperative radiotherapy (IORT) for esophageal carcinoma.
METHODSSixty patients with thoracic esophageal carcinoma underwent esophagectomy through right thoractomy, 30 patients of whom received IORT of 15 - 25 Gy.
RESULTSIn patients who underwent IORT, 2 cases of pneumonitis, 1 case of anastomotic leak and 1 case of incisional wound infection were found. In patients underwent surgery only, 1 case of thoracic empyema and 1 case of anastomotic leak were found. All the complications ultimately healed. There was no operative mortality. During the follow-up of 3 years, in patients who underwent IORT, 2 of 3 died of radiation pneumonitis 24 and 26 months after IORT with one complicated with bronchoesophageal fistula. One of 3 died of multiple lung metastases. The 3-year survival rate was 88.0% (22/25) in IORT group and 76.0% (19/25) in surgery only group.
CONCLUSIONIntraoperative radiotherapy can reduce locoregional recurrence if performed to thoracic esophageal carcinoma patients without surgical contraindication or distant metastasis. Radiation pneumonitis, a common complication difficult to manage, implies a poor prognosis and, consequently, the lung and bronchus should be protected from the radiation.
Adult ; Aged ; Combined Modality Therapy ; Esophageal Neoplasms ; mortality ; therapy ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Radiotherapy Dosage